Mucosal application of the anti-retroviral drug tenofovir, which is intended to prevent HIV transmission, has many off-target effects on the mucosa itself.

HIV transmissions into intervention communities from control communities in the Botswana/Ya Tsie trial were similar to the reverse at baseline, and 10 times more common post-baseline, concordant with a predicted benefit of a universal test-and-treat HIV prevention intervention.

A novel, hybrid segmentation technique reveals human heterogeneity in barriers towards a behavior, and is applied to characterize distinct segments in voluntary medical male circumcision.

Beyond well-recognized individual-level risk factors, HIV and hepatitis C transmission among people who inject drugs are further impacted by social and spatial network composition, and spaces in particular may represent efficient means for disseminating interventions that diffuse through the network.

Phylogenetic evidence suggests that the majority of HIV infections occurring in the UNAIDS Fast-track city Amsterdam continue to have an Amsterdam resident as source, indicating that the majority of HIV infections in Amsterdam could be prevented through city-level interventions.

CLR01 is a small molecule that could be an effective topical microbicide to eliminate HIV (and other enveloped viruses), and to antagonize host-encoded amyloid fibrils that promote HIV infection.

eLife has published a special issue containing articles that examine how cancer prevention, control, care and survivorship were impacted by the COVID-19 pandemic.

Signal-peptide cleavage of HIV-1 envelope glycoprotein is delayed because of alpha-helical structure covering the cleavage site, effecting early cleavage alters the folding pathway and resulting in localized misfolding and reduced viral fitness.

The PAVE strategy aims to provide a cost-effective, high quality ‘Screen-Triage-Treat’ approach for cervical cancer screening to save many lives.

Patients exposed to ⍺1-AR antagonists have reduced risks of mechanical ventilation and death in lower respiratory tract infection-related illnesses, highlighting the need for prospective trials assessing ⍺1-AR antagonists' effectiveness in COVID-19.